[{"id":"80dea25b-d9ea-4ed6-b053-ee4a0189b047","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878189","created_at":"2021-01-18T03:21:27.001Z","updated_at":"2024-07-02T16:36:53.866Z","phase":"Phase 1","brief_title":"A Trial In Patients With Advanced Cancer And Leukemia","source_id_and_acronym":"NCT00878189","lead_sponsor":"Pfizer","biomarkers":" NOTCH1 • NICD • HES4","pipe":" | ","alterations":" NOTCH1 expression","tags":["NOTCH1 • NICD • HES4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 06/25/2009","start_date":" 06/25/2009","primary_txt":" Primary completion: 01/10/2013","primary_completion_date":" 01/10/2013","study_txt":" Completion: 11/22/2016","study_completion_date":" 11/22/2016","last_update_posted":"2019-11-12"},{"id":"a8b7acf7-bd10-4912-aace-f566fbaf1082","acronym":"RHEA","url":"https://clinicaltrials.gov/study/NCT02338531","created_at":"2021-01-18T11:06:35.638Z","updated_at":"2024-07-02T16:37:32.462Z","phase":"Phase 2","brief_title":"Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer","source_id_and_acronym":"NCT02338531 - RHEA","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • HES4","pipe":"","alterations":" ","tags":["HER-2 • HES4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-04-29"}]